Mastutik, Gondo and Setijo Rahaju, Anny (2014) Deteksi Mutasi Gen KRAS dengan Teknik PCR RFLP sebagai Faktor Prognosis pada Adenocarcinoma Colorectal. Project Report. Universitas Airlangga, Fakultas Kedokteran Unair.

	Text (Fulltext) karil13.DeteksiMutasi.pdf Restricted to Registered users only Download (1MB) | Request a copy
	Text (Peerreview) peerreview13-DeteksiMutasi.pdf Restricted to Registered users only Download (1MB) | Request a copy
	Text (Abstract) Abstrak13.pdf Restricted to Registered users only Download (768kB) | Request a copy

Abstract

Colorectal cancer is one of the most common cancers in the world. Important molecular target for treatment of colorectal cancer is the Epidermal Growth Factor Receptor (EGFR) that treatment with anti-EGFR monoclonal antibody (cetuximab and panitumumab) as a ligand that binds to the EGFR. Cetuximab and panitumumab bind to EGFR and phosphorylated EGFR prevent and block ligand activation-induced EGFR tyrosine kinase, thereby preventing activation of signaling downstream of PI3K and RAS / MEK / ERK pathway. This results in barriers to cellular proliferation and induce apoptosis. cross sectional analytic aimed to obtain data identifying the KRAS gene in a variety of dosage colorectal adenocarcinoma grade paraffin blocks Hospital Dr Soetomo. Samples were collected at the Department / SMF / Installation Pathology Faculty of Medicine, University of Airlangga - Hospital Dr Soetomo began January 1, 2013 until December 31, 2013. KRAS mutation detection was performed using PCR restriction fragment length polymorphism (PCR RFLP). KRAS gene mutations in this study is 733% (7/21), which occurs in codon 12 and no mutation at codon 13. The results of PCR RFLP with the enzyme MvaI at codon 12 showed that there were 33% (7/21) mutations in codon 12, whereas restriction enzymes BsuRI at codon 13 of the PCR products showed no mutations in the KRAS gene. The mutation occurs codon 12 GGT> GCT and 12 GGT> GAT that cause amino acid changes Gly12Ala and Gly12Asp. Suggestions put forward in this study were PCR RFLP technique can be used for identification of the KRAS gene mutation paafin sample block. Identification of these mutations can be used as a basis for granting anti-EGFR monoclonal antibody therapy that is in case of KRAS gene mutations, the therapy does not need to be done and if the status is still wild-type KRAS gene therapy it is necessary to cause tumor regression period.

Actions (login required)

View Item